Abstract:AimMultifocal desmoplastic infantile ganglioglioma/astrocytoma (DIA/DIG) has rarely been reported. Here, two cases have been presented, reviewing the literature and proposed treatment algorithms for this rare tumor.Patients and MethodsWe report two patients diagnosed with multifocal DIA/DIGs in West China Hospital. In addition, a literature review was performed, in October 2019, on case reports of DIA/DIGs with multifocal lesions. The clinical and radiological features, treatment, and outcome of this rare dise… Show more
“…DITs often occur in infants and rarely in adults ( 2 , 9 ), which is divided into the infant group (<5 years old) and the non-infant group (>5 years old) ( 10 ). These low-grade tumors usually have a good prognosis, but some have malignant features, such as multiple intracranial lesions ( 3 , 4 ), postoperative recurrence ( 2 , 4 , 5 ), meningeal diffusion, and metastasis ( 6 ).…”
Section: Discussionmentioning
confidence: 99%
“…If surgical resection is complete, the patient has a good prognosis without radiotherapy and chemotherapy. However, the benign nature of this tumor has been questioned with successive reports of atypical, aggressive, and multifocal DITs (2)(3)(4)(5)(6). Here, we report a rare case of DITs in a non-infantile who underwent a malignant transformation after surgical resection 12 years later, followed by spread and metastasis.…”
Desmoplastic infantile tumors (DITs) are rare benign intracranial tumors in infants with benign biological behavior and rare malignant transformation characteristics. We present a DIT case that underwent malignant transformation and metastasis. A 6-year-old girl presented with DITs and underwent surgical resection. 12 years later, the tumor recurred and underwent surgical resection again. The pathology report confirmed the lesion to be a glioblastoma multiforme. She received adjuvant treatment. A year after the surgical operation of the lesions, she had intraspinal metastasis and underwent surgical resection again. Multiple spinal cord metastases were subsequently identified in the patient. The patient’s condition exhibited severe deterioration during the follow-up period. This case report focuses on the occurrence of DITs and their potential malignant transformation, as assessed through computed tomography and magnetic resonance imaging.
“…DITs often occur in infants and rarely in adults ( 2 , 9 ), which is divided into the infant group (<5 years old) and the non-infant group (>5 years old) ( 10 ). These low-grade tumors usually have a good prognosis, but some have malignant features, such as multiple intracranial lesions ( 3 , 4 ), postoperative recurrence ( 2 , 4 , 5 ), meningeal diffusion, and metastasis ( 6 ).…”
Section: Discussionmentioning
confidence: 99%
“…If surgical resection is complete, the patient has a good prognosis without radiotherapy and chemotherapy. However, the benign nature of this tumor has been questioned with successive reports of atypical, aggressive, and multifocal DITs (2)(3)(4)(5)(6). Here, we report a rare case of DITs in a non-infantile who underwent a malignant transformation after surgical resection 12 years later, followed by spread and metastasis.…”
Desmoplastic infantile tumors (DITs) are rare benign intracranial tumors in infants with benign biological behavior and rare malignant transformation characteristics. We present a DIT case that underwent malignant transformation and metastasis. A 6-year-old girl presented with DITs and underwent surgical resection. 12 years later, the tumor recurred and underwent surgical resection again. The pathology report confirmed the lesion to be a glioblastoma multiforme. She received adjuvant treatment. A year after the surgical operation of the lesions, she had intraspinal metastasis and underwent surgical resection again. Multiple spinal cord metastases were subsequently identified in the patient. The patient’s condition exhibited severe deterioration during the follow-up period. This case report focuses on the occurrence of DITs and their potential malignant transformation, as assessed through computed tomography and magnetic resonance imaging.
BackgroundThe present study aims to develop a metabolic gene signature to evaluate the survival rate of ovarian cancer (OC) patients and analyze the potential mechanisms of metabolic genes in OC because the difficulty in early detection of OC often leads to poor treatment outcomes.MethodsA non‐negative matrix factorization algorithm was applied to determine molecular subtypes according to metabolism genes. To build a risk prognosis model, least absolute shrinkage and selection operator multivariate Cox analysis was carried out with weighted correlation network analysis (WCGNA). Glycolytic flux and mitochondrial function were evaluated by conducting seahorse analysis.ResultsOn the basis of metabolism‐related genes, the two subtypes of OC samples present in The Cancer Genome Atlas database were distinguished. An analysis of WGCNA identified 1056 genes. Lastly, a 10‐gene signature (CMAS, ADH1B, PLA2G2D, BHMT, CACNA1C, AADAC, ALOX12, CYP2R1, SCN1B and ME1) was constructed that demonstrated promising performance in predicting outcome in patients with OC. The RiskScore of the gene signature was linked to microenvironment cell infiltration and immune checkpoint. Higher RiskScores were associated with poorer results for OC patients. Seahorse analysis shows the influence of CMAS in cell energy metabolism.ConclusionsIn the present study, a novel marker for evaluating the survival of OC patients was developed through the creation of a gene signature incorporating metabolism‐related genes. Our knowledge of immunotherapy and microenvironment cell infiltration may be enriched by evaluating metabolism‐related gene modification patterns.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.